The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial
Open accessAbstract
Importance: It is unknown whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) have a positive, neutral, or negative effect on clinical outcomes in patients with coronavirus disease 2019 (COVID-19). Objective: To determine whether discontinuation compared with continuation of ACEIs or ARBs changed the number of days alive and out of the hospital through 30 days. Design, Setting, and Participants: A randomized clinical trial of 659 patients hospitalized in Brazil with mild to moderate COVID-19 who were taking ACEIs or ARBs prior to hospitalization (enrolled: April 9-June 26, 2020; final follow-up: July 26, 2020). Interventions: Discontinuation (n = 334) or continuation (n = 325) of ACEIs or ARBs. Main Outcomes and Measures: The primary outcome was the number of days alive and out of the hospital through 30 days. Secondary outcomes included death, cardiovascular death, and COVID-19 progression. Results: Among 659 patients, the median age was 55.1 years (interquartile range [IQR], 46.1-65.0 years), 14.7% were aged 70 years or older, 40.4% were women, and 100% completed the trial. The median time from symptom onset to hospital admission was 6 days (IQR, 4-9 days) and 27.2% of patients had an oxygen saturation of less than 94% of room air at baseline. In terms of clinical severity, 57.1% of patients were considered mild at hospital admission and 42.9% were considered moderate. There was no significant difference in the number of days alive and out of the hospital in patients in the discontinuation group (mean, 21.9 days [SD, 8 days]) vs patients in the continuation group (mean, 22.9 days [SD, 7.1 days]) and the mean ratio was 0.95 (95% CI, 0.90-1.01). There also was no statistically significant difference in death (2.7% for the discontinuation group vs 2.8% for the continuation group; odds ratio [OR], 0.97 [95% CI, 0.38-2.52]), cardiovascular death (0.6% vs 0.3%, respectively; OR, 1.95 [95% CI, 0.19-42.12]), or COVID-19 progression (38.3% vs 32.3%; OR, 1.30 [95% CI, 0.95-1.80]). The most common adverse events were respiratory failure requiring invasive mechanical ventilation (9.6% in the discontinuation group vs 7.7% in the continuation group), shock requiring vasopressors (8.4% vs 7.1%, respectively), acute myocardial infarction (7.5% vs 4.6%), new or worsening heart failure (4.2% vs 4.9%), and acute kidney failure requiring hemodialysis (3.3% vs 2.8%). Conclusions and Relevance: Among patients hospitalized with mild to moderate COVID-19 and who were taking ACEIs or ARBs before hospital admission, there was no significant difference in the mean number of days alive and out of the hospital for those assigned to discontinue vs continue these medications. These findings do not support routinely discontinuing ACEIs or ARBs among patients hospitalized with mild to moderate COVID-19 if there is an indication for treatment. Trial Registration: ClinicalTrials.gov Identifier: NCT04364893.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease 2019 (COVID-19)
Guo, T., Fan, Y., Chen, M., Wu, X., Zhang, L., He, T., Wang, H., Wan, J., Wang, X., & Lu, Z. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1017 · Cited by 4,194
Generalized additive models for location, scale and shape.
Rigby, R. A., & Stasinopoulos, D. M. (2005) · Journal of the Royal Statistical Society Series C: Applied Statistics · doi:10.1111/j.1467-9876.2005.00510.x · Cited by 3,228
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P., Sarao, R., Wada, T., Leong-Poi, H., et al. (2005) · Nature · doi:10.1038/nature03712 · Cited by 2,453
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J.-C., Turner, A. J., Raizada, M. K., Grant, M. B., & Oudit, G. Y. (2020) · Circulation Research · doi:10.1161/circresaha.120.317015 · Cited by 1,882
Hung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., Ng, Y.-Y., Lo, J., Chan, J., Tam, A. R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31042-4 · Cited by 1,455
Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J.-J., Xie, J., Liu, Y.-M., Zhao, Y.-C., Huang, X., Lin, L., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.317134 · Cited by 1,133
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
Cavalcanti, A. B., Zampieri, F. G., Rosa, R. G., Azevedo, L. C. P., Veiga, V. C., Avezum, A., Damiani, L. P., Marcadenti, A., Kawano-Dourado, L., Lisboa, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2019014 · Cited by 1,083
Self-citationRenin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
Mancia, G., Rea, F., Ludergnani, M., Apolone, G., & Corrao, G. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2006923 · Cited by 1,073
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
Reynolds, H. R., Adhikari, S., Pulgarin, C., Troxel, A. B., Iturrate, E., Johnson, S. B., Hausvater, A., Newman, J. D., Berger, J. S., Bangalore, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2008975 · Cited by 1,063
Hellström (2019) · doi:10.21037/atm · Cited by 798
Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms
Sattar, N., McInnes, I. B., & McMurray, J. J. V. (2020) · Circulation · doi:10.1161/circulationaha.120.047659 · Cited by 704
Meng, J., Xiao, G., Zhang, J., He, X., Ou, M., Bi, J., Yang, R., Di, W., Wang, Z., Li, Z., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1746200 · Cited by 619
Li, J., Wang, X., Chen, J., Zhang, H., & Deng, A. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1624 · Cited by 541
de Abajo, F. J., Rodríguez-Martín, S., Lerma, V., Mejía-Abril, G., Aguilar, M., García-Luque, A., Laredo, L., Laosa, O., Centeno-Soto, G. A., Ángeles Gálvez, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31030-8 · Cited by 408
Mehta, N., Kalra, A., Nowacki, A. S., Anjewierden, S., Han, Z., Bhat, P., Carmona-Rubio, A. E., Jacob, M., Procop, G. W., Harrington, S., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1855 · Cited by 400
Patel, A. B., & Verma, A. (2020) · JAMA · doi:10.1001/jama.2020.4812 · Cited by 378
Furtado, R. H. M., Berwanger, O., Fonseca, H. A., Corrêa, T. D., Ferraz, L. R., Lapa, M. G., Zampieri, F. G., Veiga, V. C., Azevedo, L. C. P., Rosa, R. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31862-6 · Cited by 360
Self-citationJoint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19
Bozkurt, B., Kovacs, R., & Harrington, B. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.04.013 · Cited by 355
Angiotensin Converting Enzyme 2: A Double-Edged Sword
Wang, K., Gheblawi, M., & Oudit, G. Y. (2020) · Circulation · doi:10.1161/circulationaha.120.047049 · Cited by 265
Fonarow, G. C., Abraham, W. T., Albert, N. M., Stough, W. G., Gheorghiade, M., Greenberg, B. H., O'Connor, C. M., Sun, J. L., Yancy, C. W., & Young, J. B. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.048 · Cited by 257
Bean, D. M., Kraljevic, Z., Searle, T., Bendayan, R., Kevin, O., Pickles, A., Folarin, A., Roguski, L., Noor, K., Shek, A., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1924 · Cited by 229
Days Alive and Out of Hospital: Validation of a Patient-centered Outcome for Perioperative Medicine
Jerath, A., Austin, P. C., & Wijeysundera, D. N. (2019) · Anesthesiology · doi:10.1097/aln.0000000000002701 · Cited by 220
Remdesivir for the treatment of COVID-19
Ansems, K., Grundeis, F., Dahms, K., Mikolajewska, A., Thieme, V., Piechotta, V., Metzendorf, M.-I., Stegemann, M., Benstoem, C., & Fichtner, F. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014962 · Cited by 200
Lópes, R. D., Macedo, A. V. S., Silva, P. G. M. D. B. E., Moll-Bernardes, R. J., Feldman, A., Arruda, G., de Souza, A. S., de Albuquerque, D. C., Barbosa, L. M., Santos, M. F., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.05.002 · Cited by 148
Self-citationSARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy
Chung, M. K., Karnik, S. S., Saef, J., Bergmann, C. C., Barnard, J., Lederman, M. M., Tilton, J. C., Cheng, F., Harding, C. V., Young, J. B., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102907 · Cited by 143
ACE2: Angiotensin II/Angiotensin-(1–7) Balance in Cardiac and Renal Injury
Varagić, J., Ahmad, S., Nagata, S., & Ferrario, C. M. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0420-5 · Cited by 126
Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
Jarcho, J. A., Ingelfinger, J. R., Hamel, M. B., D’Agostino, R. B., & Harrington, D. P. (2020) · New England Journal of Medicine · doi:10.1056/nejme2012924 · Cited by 126
Khera, R., Clark, C. N., Lu, Y., Guo, Y., Ren, S., Truax, B., Spatz, E. S., Murugiah, K., Lin, Z., Omer, S. B., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.018086 · Cited by 98
Fanaroff, A. C., Cyr, D. D., Neely, M. L., Bakal, J. A., White, H. D., Fox, K. A. A., Armstrong, P. W., Lópes, R. D., Ohman, E. M., & Roe, M. T. (2018) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.004755 · Cited by 93
Pharmacologic modulation of ACE2 expression
Soler, M. J., Barrios, C., Oliva, R., & BATLLE, D. C. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0076-0 · Cited by 92
Bravi, F., Flacco, M. E., Carradori, T., Volta, C. A., Cosenza, G., Togni, A. D., Martellucci, C. A., Parruti, G., Mantovani, L. G., & Manzoli, L. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235248 · Cited by 87
Pan, W. D., Zhang, J., Wang, M., Ye, J., Xu, Y. Q., Shen, B., He, H., Wang, Z., Ye, D., Zhao, M., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15289 · Cited by 83
The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension
Huang, Z., Cao, J., Yao, Y., Jin, X., Luo, Z., Xue, Y., Zhu, C., Song, Y., Wang, Y., Zou, Y., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.229 · Cited by 80
Randomized Trials Versus Common Sense and Clinical Observation
Fanaroff, A. C., Califf, R. M., Harrington, R. A., Granger, C. B., McMurray, J. J. V., Patel, M. R., Bhatt, D. L., Windecker, S., Hernandez, A. F., Gibson, C. M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.069 · Cited by 77
Self-citationIs Hypertension a Real Risk Factor for Poor Prognosis in the COVID-19 Pandemic?
Drager, L. F., Pio-Abreu, A., Lópes, R. D., & Bortolotto, L. A. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-01057-x · Cited by 51
Rigorous Clinical Trial Design in Public Health Emergencies Is Essential
Ellenberg, S. S., Keusch, G. T., Babiker, A. G., Edwards, K. M., Lewis, R. J., Lundgren, J. D., Wells, C. D., Wabwire‐Mangen, F., & McAdam, K. P. W. J. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix1032 · Cited by 29
Ah, Y., Lee, J., Choi, Y. J., Kim, B., Choi, K. H., Kong, J., Oh, J. M., Shin, W. G., & Lee, H. (2015) · Journal of Korean Medical Science · doi:10.3346/jkms.2015.30.12.1800 · Cited by 25
New Approaches to Conducting Randomized Controlled Trials
Fanaroff, A. C., Califf, R. M., & Lópes, R. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.043 · Cited by 25
Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers
Poulter, N. R., Hughes, A. D., Williams, B., Brady, A. J. B., & McInnes, G. T. (2006) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2006.008 · Cited by 9
Elijovich, F., & Laffer, C. L. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15712 · Cited by 3
Cited by
Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., Cook, J. R., Nordvig, A. S., Shalev, D., Sehrawat, T. S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01283-z · Cited by 4,862
Drug treatments for covid-19: living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Zeraatkar, D., Kum, E., Qasim, A., Díaz Martinez, J. P., Izcovich, A., Rochwerg, B., Lamontagne, F., Han, M. A., et al. (2020) · BMJ · doi:10.1136/bmj.m2980 · Cited by 846
Long-term complications of COVID-19
Desai, A. D., Lavelle, M., Boursiquot, B. C., & Wan, E. Y. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00375.2021 · Cited by 415
(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
Self, W. H., Shotwell, M. S., Gibbs, K. W., de Wit, M., Files, D. C., Harkins, M., Hudock, K. M., Merck, L. H., Moskowitz, A., Apodaca, K. D., et al. (2023) · JAMA · doi:10.1001/jama.2023.3546 · Cited by 52
Metadata
- Authors
- Lopes, R. D., Macedo, A. V. S., de Barros E Silva, P. G. M., Moll-Bernardes, R. J., dos Santos, T. M., Mazza, L., Feldman, A., D’Andréa Saba Arruda, G., de Albuquerque, D. C., Camiletti, A. S., de Sousa, A. S., de Paula, T. C., Giusti, K. G. D., Domiciano, R. A. M., Noya-Rabelo, M. M., Hamilton, A. M., Loures, V. A., Dionísio, R. M., Furquim, T. A. B., De Luca, F. A., dos Santos Sousa, Í. B., Bandeira, B. S., Zukowski, C. N., de Oliveira, R. G. G., Ribeiro, N. B., de Moraes, J. L., Petriz, J. L. F., Pimentel, A. M., Miranda, J. S., de Jesus Abufaiad, B. E., Gibson, C. M., Granger, C. B., Alexander, J. H., de Souza, O. F., & BRACE CORONA Investigators
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-01-19
- Volume
- 325
- Issue
- 3
- Pages
- 254
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3122900688
- Cited by
- 364
- References
- 43
- FWCI
- 25.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.